E-Note for Adult
Medicine
Stat | Lytes |
Drugs | ID |
AIDS | Heart |
Lungs | Kidneys |
GI | Rheum |
Heme-Onc | Endo |
Neuro | Derm |
Toxic | Travel |
Misc. |
Resources |
Home |
Infectious-Diseases FUO Fever & Rash Brucellosis Psittacosis
Sexual Transmitted Diseases
|
Sexually Transmitted Disease Rx Guidelines -
CDC 1998 MMWR 1998;47(No. RR-1) http://www.cdc.gov/nchstp/dstd/STD98TG.HTM DISEASES CHARACTERIZED BY GENITAL ULCERS (genital herpes, syphilis, or chancroid) Evaluation of all patients who have genital ulcers should include a serologic test for syphilis and diagnostic evaluation for herpes. Specific tests for the evaluation of genital ulcers include the following:
A health-care provider often must treat a patient before test results are
available. In such a circumstance, the clinician should treat for the diagnosis
considered most likely. If the diagnosis is unclear, many experts recommend
treatment for syphilis, or for both syphilis and chancroid if the patient
resides in a community in which H. ducreyi is a significant cause of genital
ulcers, especially when diagnostic capabilities for chancroid or syphilis
are not ideal. However, even after complete diagnostic evaluation, at least
25% of patients who have genital ulcers have no laboratory-confirmed diagnosis.
Chancroid
Treatment of Chancroid
NOTE: Ciprofloxacin is contraindicated for pregnant and lactating women and
for persons aged less than 18 years.
Management of Sex Partners
HIV-infected patients who have chancroid should be monitored closely. Such
patients may require longer courses of therapy than those recommended for
HIV-negative patients. Healing may be slower among HIV-infected patients,
and treatment failures occur with any regimen.
Genital Herpes Simplex Virus (HSV-2) Infection
Recommended Regimens
Higher dosages of acyclovir (i.e., 400 mg orally five times a day) were used
in treatment studies of first-episode herpes proctitis and first-episode
oral infection, including stomatitis or pharyngitis. It is unclear whether
these forms of mucosal infection require higher doses of acyclovir than used
for genital herpes. Valacyclovir and famciclovir probably are also effective
for acute HSV proctitis or oral infection, but clinical experience is lacking.
Patients should be advised to abstain from sexual activity when lesions or
prodromal symptoms are present and encouraged to inform their sex partners
that they have genital herpes. The use of condoms during all sexual exposures
with new or uninfected sex partners should be encouraged.
Sexual transmission of HSV can occur during asymptomatic periods. Asymptomatic
viral shedding occurs more frequently in patients who have genital HSV-2
infection than HSV-1 infection and in patients who have had genital herpes
for less than 12 months. Such patients should be counseled to prevent spread
of the infection.
The risk for neonatal infection should be explained to all patients, including
men. Childbearing-aged women who have genital herpes should be advised to
inform health-care providers who care for them during pregnancy about the
HSV infection.
Most patients with first-episode genital HSV-2 infection will have recurrent
episodes of genital lesions. Episodic or suppressive antiviral therapy might
shorten the duration of lesions or ameliorate recurrences. Because many patients
benefit from antiviral therapy, options for treatment should be discussed
with all patients. When treatment is started during the prodrome or within 1 day after onset of lesions, many patients who have recurrent disease benefit from episodic therapy.
If episodic treatment of recurrences is chosen, the patient should be provided
with antiviral therapy, or a prescription for the medication, so that treatment
can be initiated at the first sign of prodrome or genital lesions.
Daily suppressive therapy reduces the frequency of genital herpes recurrences
by greater than or equal to 75% among patients who have frequent recurrences
(i.e., six or more recurrences per year). Safety and efficacy have been
documented among patients receiving daily therapy with acyclovir for as long
as 6 years, and with valacyclovir and famciclovir for 1 year. Suppressive
therapy has not been associated with emergence of clinically significant
acyclovir resistance among immunocompetent patients. After 1 year of continuous
suppressive therapy, discontinuation of therapy should be discussed with
the patient to assess the patient's psychological adjustment to genital herpes
and rate of recurrent episodes, as the frequency of recurrences decreases
over time in many patients. Insufficient experience with famciclovir and
valacyclovir prevents recommendation of these drugs for greater than 1 year.
Suppressive treatment with acyclovir reduces but does not eliminate asymptomatic
viral shedding. Therefore, the extent to which suppressive therapy may prevent
HSV transmission is unknown. Recommended Regimens for Episodic Recurrent Infection
Recommended Regimens for Daily Suppressive Therapy
Rx of Severe Disease
Management of Sex Partners Most of the available HSV antibody tests do not accurately discriminate between HSV-1 and HSV-2 antibodies, and their use is not currently recommended.
Sensitive and type-specific serum antibody assays may become commercially
available and contribute to future intervention strategies.
Special Considerations
Herpes Simplex Infection in HIV Infection patients: The dosage of antiviral drugs for HIV-infected patients is controversial, but clinical experience strongly suggests that immunocompromised patients benefit from increased doses of antiviral drugs. Regimens such as acyclovir 400 mg orally three to five times a day, as used for other immunocompromised patients, have been useful. Therapy should be continued until clinical resolution is attained. Famciclovir 500 mg twice a day has been effective in decreasing both the rate of recurrences and the rate of subclinical shedding among HIV-infected patients. In immunocompromised patients, valacyclovir in doses of 8 g per day has been associated with a syndrome resembling either hemolytic uremic syndrome or thrombotic thrombocytopenic purpura. However, in the doses recommended for treatment of genital herpes, valacyclovir, acyclovir, and famciclovir probably are safe for use in immunocompromised patients.
For severe cases, acyclovir 5 mg/kg IV every 8 hours may be required. If lesions persist in a patient receiving acyclovir treatment, resistance of the HSV strain to acyclovir should be suspected. Such patients should be managed in consultation with an expert. For severe cases caused by proven or suspected acyclovir-resistant strains, alternate therapy should be administered. All acyclovir-resistant strains are resistant to valacyclovir, and most are resistant to famciclovir. Foscarnet, 40 mg/kg body weight IV every 8 hours until clinical resolution is attained, is often effective for treatment of acyclovir-resistant genital herpes. Topical cidofovir gel 1% applied to the lesions once daily for 5
consecutive days also might be effective.
Pregnancy The safety of systemic acyclovir and valacyclovir therapy in pregnant women has not been established. Glaxo-Wellcome, Inc., in cooperation with CDC, maintains a registry to assess the use and effects of acyclovir and valacyclovir during pregnancy. Women who receive acyclovir or valacyclovir during
pregnancy should be reported to this registry; telephone (800) 722-9292,
extension 38465. Current registry findings do not indicate an increased risk for major birth defects after acyclovir treatment (i.e., in comparison with the general population). These findings provide some assurance in counseling women who have had prenatal exposure to acyclovir. The accumulated case histories represent an insufficient sample for reaching reliable and definitive conclusions regarding the risks associated with acyclovir treatment during pregnancy. Prenatal exposure
to valacyclovir and famciclovir is too limited to provide useful information
on pregnancy outcomes. The first clinical episode of genital herpes during pregnancy may be treated with oral acyclovir. In the presence of life-threatening maternal HSV infection (e.g., disseminated infection, encephalitis, pneumonitis, or hepatitis), acyclovir administered IV is indicated. Investigations of acyclovir use among pregnant women suggest that acyclovir treatment near term might reduce the rate of abdominal deliveries among women who have frequently recurring or newly acquired genital herpes by decreasing the incidence of active lesions. However, routine administration of acyclovir to pregnant women who have a history of recurrent genital
herpes is not recommended at this time.
Perinatal Infection Most mothers of infants who acquire neonatal herpes lack histories of clinically evident genital herpes. The risk for transmission to the neonate from an infected mother is high among women who acquire genital herpes near the time of delivery (30%-50%) and is low among women who have a history of recurrent herpes at term and women who acquire genital HSV during the first half of pregnancy (3%). Therefore, prevention of neonatal herpes should emphasize prevention of acquisition of genital HSV infection during late pregnancy. Susceptible women whose partners have oral or genital HSV infection, or those whose sex partners' infection status is unknown, should be counseled to avoid unprotected genital and oral sexual contact during late pregnancy. The results of
viral cultures during pregnancy do not predict viral shedding at the time
of delivery, and such cultures are not indicated routinely. At the onset of labor, all women should be examined and carefully questioned regarding whether they have symptoms of genital herpes. Infants of women who do not have symptoms or signs of genital herpes infection or its prodrome may be delivered vaginally. Abdominal delivery does not completely eliminate the
risk for HSV infection in the neonate. Infants exposed to HSV during birth, as proven by virus isolation or presumed by observation of lesions, should be followed carefully. Some authorities recommend that such infants undergo surveillance cultures of mucosal surfaces to detect HSV infection before development of clinical signs. Available data do not support the routine use of acyclovir for asymptomatic infants exposed during birth through an infected birth canal, because the risk for infection in most infants is low. However, infants born to women who acquired genital herpes near term are at high risk for neonatal herpes, and some experts recommend acyclovir therapy for these infants. Such pregnancies and newborns should be managed in consultation with an expert. All infants who have evidence of
neonatal herpes should be promptly evaluated and treated with systemic acyclovir
(19). Acyclovir 30-60 mg/
Granuloma Inguinale (Donovanosis)
Treatment
Treatment appears to halt progressive destruction of tissue, although prolonged
duration of therapy often is required to enable granulation and
re-epithelialization of the ulcers. Relapse can occur 6-18 months later despite
effective initial therapy.
Recommended Regimens
For any of the above regimens, the addition of an aminoglycoside (gentamicin
1 mg/kg IV every 8 hours) should be considered if lesions do not respond
within the first few days of therapy.
Special Considerations
HIV Infection
Lymphogranuloma Venereum
When most patients seek medical care, they no longer have the self-limited
genital ulcer that sometimes occurs at the inoculation site. The diagnosis
usually is made serologically and by exclusion of other causes of inguinal
lymphadenopathy or genital ulcers.
Treatment
Recommended Regimens
The activity of azithromycin against C. trachomatis suggests that it may
be effective in multiple doses over 2-3 weeks, but clinical data regarding
its use are lacking.
Follow-Up
Management of Sex Partners
Special Considerations
Syphilis
Diagnostic Considerations and Use of Serologic Tests
Sequential serologic tests should be performed by using the same testing
method (e.g., VDRL or RPR), preferably by the same laboratory. The VDRL and
RPR are equally valid, but quantitative results from the two tests cannot
be compared directly because RPR titers often are slightly higher than VDRL
titers.
HIV-infected patients can have abnormal serologic test results (i.e., unusually
high, unusually low, and fluctuating titers). For such patients with clinical
syndromes suggestive of early syphilis, use of other tests (e.g., biopsy
and direct microscopy) should be considered. However, for most HIV-infected
patients, serologic tests appear to be accurate and reliable for the diagnosis
of syphilis and for evaluation of treatment response. No single test can be used to diagnose all cases of neurosyphilis. The diagnosis of neurosyphilis can be made based on various combinations of reactive serologic test results, abnormalities of cerebrospinal fluid (CSF) cell count or protein, or a reactive VDRL-CSF with or without clinical manifestations. The CSF leukocyte count usually is elevated (greater than 5 WBCs/mm3) when neurosyphilis is present, and it also is a sensitive measure of the effectiveness of
therapy. The VDRL-CSF is the standard serologic test for CSF; when reactive
in the absence of substantial contamination of CSF with blood, it is considered
diagnostic of neurosyphilis. However, the VDRL-CSF may be nonreactive when
neurosyphilis is present. Some experts recommend performing an FTA-ABS test
on CSF. The CSF FTA-ABS is less specific (i.e., yields more false-positive
results) for neurosyphilis than the VDRL-CSF. However, the test is believed
to be highly sensitive, and some experts believe that a negative CSF FTA-ABS
test excludes neurosyphilis.
Treatment
The efficacy of penicillin for the treatment of syphilis was well established
through clinical experience before the value of randomized controlled clinical
trials was recognized. Therefore, almost all the recommendations for the
treatment of syphilis are based on expert opinion reinforced by case series,
clinical trials, and 50 years of clinical experience.
Parenteral penicillin G is the only therapy with documented efficacy for
neurosyphilis or for syphilis during pregnancy. Patients who report a penicillin
allergy, including pregnant women with syphilis in any stage and patients
with neurosyphilis, should be desensitized and treated with penicillin. Skin
testing for penicillin allergy may be useful in some settings (see Management
of Patients Who Have a History of Penicillin Allergy), because the minor
determinants needed for penicillin skin testing are unavailable commercially.
The Jarisch-Herxheimer reaction is an acute febrile reaction -- often accompanied
by headache, myalgia, and other symptoms -- that might occur within the first
24 hours after any therapy for syphilis; patients should be advised of this
possible adverse reaction. The Jarisch-Herxheimer reaction often occurs among
patients who have early syphilis. Antipyretics may be recommended, but no
proven methods prevent this reaction. The Jarisch-Herxheimer reaction may
induce early labor or cause fetal distress among pregnant women. This concern
should not prevent or delay therapy (see Syphilis During Pregnancy).
Management of Sex Partners
Persons who were exposed within the 90 days preceding the diagnosis of primary,
secondary, or early latent syphilis in a sex partner might be infected even
if seronegative; therefore, such persons should be treated presumptively.
Persons who were exposed greater than 90 days before the diagnosis of primary,
secondary, or early latent syphilis in a sex partner should be treated
presumptively if serologic test results are not available immediately and
the opportunity for follow-up is uncertain.
For purposes of partner notification and presumptive treatment of exposed
sex partners, patients with syphilis of unknown duration who have high
nontreponemal serologic test titers (i.e., greater than or equal to 1:32)
may be considered as having early syphilis. However, serologic titers should
not be used to differentiate early from late latent syphilis for the purpose
of determining treatment (see section regarding treatment of latent syphilis).
Long-term sex partners of patients who have late syphilis should be evaluated
clinically and serologically for syphilis and treated on the basis of the
findings of the evaluation.
The time periods before treatment used for identifying at-risk sex partners
are a) 3 months plus duration of symptoms for primary syphilis, b) 6 months
plus duration of symptoms for secondary syphilis, and c) 1 year for early
latent syphilis.
Primary and Secondary Syphilis
Recommended Regimen for Adults
Recommended Regimen for Children
Other Management Considerations
Patients who have syphilis and who also have symptoms or signs suggesting
neurologic disease (e.g., meningitis) or ophthalmic disease (e.g., uveitis)
should be evaluated fully for neurosyphilis and syphilitic eye disease; this
evaluation should include CSF analysis and ocular slit-lamp examination.
Such patients should be treated appropriately according to the results of
this evaluation.
Invasion of CSF by T. pallidum accompanied by CSF abnormalities is common
among adults who have primary or secondary syphilis. However, neurosyphilis
develops in only a few patients after treatment with the regimens described
in this report. Therefore, unless clinical signs or symptoms of neurologic
or ophthalmic involvement are present, lumbar puncture is not recommended
for routine evaluation of patients who have primary or secondary syphilis.
Follow-Up Patients who have signs or symptoms that persist or recur or who have a sustained fourfold increase in nontreponemal test titer (i.e., in comparison with either the baseline titer or a subsequent result) probably failed treatment or were reinfected. These patients should be re-treated after reevaluation for HIV infection.
Unless reinfection with T. pallidum is certain, a lumbar puncture also should
be performed. Failure of nontreponemal test titers to decline fourfold within 6 months after therapy for primary or secondary syphilis identifies persons at risk for treatment failure. Such persons should be reevaluated for HIV infection. Optimal management of such patients is unclear. At a minimum, these patients should have additional clinical and serologic follow-up. HIV-infected patients should be evaluated more frequently (i.e., at 3-month intervals instead of 6-month intervals).
If additional follow-up cannot be ensured, re-treatment is recommended. Some
experts recommend CSF examination in such situations.
When patients are re-treated, most experts recommend re-treatment with three
weekly injections of benzathine penicillin G 2.4 million units IM, unless
CSF examination indicates that neurosyphilis is present.
Management of Sex Partners
Special Considerations
Recommended Regimens
Pharmacologic and bacteriologic considerations suggest that ceftriaxone should
be effective, but data concerning ceftriaxone are limited and clinical experience
is insufficient to enable identification of late failures. The optimal dose
and duration have not been established for ceftriaxone, but a suggested daily
regimen of 1 g may be considered if treponemacidal levels in the blood can
be maintained for 8-10 days. Single-dose ceftriaxone therapy is not effective
for treating syphilis.
For nonpregnant patients whose compliance with therapy and follow-up can
be ensured, an alternative regimen is erythromycin 500 mg orally four times
a day for 2 weeks. However, erythromycin is less effective than the other
recommended regimens. Patients whose compliance with therapy or follow-up cannot be ensured should be desensitized and treated with penicillin. Skin testing for penicillin allergy
may be useful in some circumstances in which the reagents and expertise to
perform the test adequately are available (see Management of Patients Who
Have a History of Penicillin Allergy).
Pregnancy
HIV Infection
Latent Syphilis Patients who have latent syphilis and who acquired syphilis within the preceding year are classified as having early latent syphilis. Patients can be demonstrated as having early latent syphilis if, within the year preceding the evaluation, they had a) a documented seroconversion, b) unequivocal symptoms of primary or secondary syphilis, or c) a sex partner who had primary, secondary, or early latent syphilis. Almost all other patients have latent syphilis of unknown duration and should be managed as if they had late latent syphilis. Nontreponemal serologic titers usually are higher during early latent syphilis than late latent syphilis.
However, early latent syphilis cannot be reliably distinguished from late
latent syphilis solely on the basis of nontreponemal titers. Regardless of
the level of the nontreponemal titers, patients in whom the illness does
not meet the definition of early syphilis should be treated as if they have
late latent infection. All sexually active women with reactive nontreponemal
serologic tests should have a pelvic examination before syphilis staging
is completed to evaluate for internal mucosal lesions. All patients who have
syphilis should be tested for HIV infection.
Treatment
Recommended Regimens for Adults
Recommended Regimens for Children
records should be reviewed to assess whether the child has congenital or
acquired syphilis (see Congenital Syphilis). Older children with acquired
latent syphilis should be evaluated as described for adults and treated using
the following pediatric regimens (see Sexual Assault or Abuse of Children).
These regimens are for non-allergic children who have acquired syphilis and
whose results of the CSF examination were normal.
Other Management Considerations
If dictated by circumstances and patient preferences, a CSF examination may
be performed for patients who do not meet these criteria. If a CSF examination
is performed and the results indicate abnormalities consistent with
neurosyphilis, the patient should be treated for neurosyphilis (see
Neurosyphilis).
Follow-Up
Management of Sex Partners
Special Considerations
Recommended Regimens
Pregnancy
HIV Infection
Tertiary Syphilis
Recommended Regimens
Follow-Up
Management of Sex Partners
Special Considerations
Pregnancy
HIV Infection
Neurosyphilis
Syphilitic uveitis or other ocular manifestations frequently are associated
with neurosyphilis; patients with these symptoms should be treated according
to the recommendations for neurosyphilis. A CSF examination should be performed
for all such patients to identify those with abnormalities who should have
follow-up CSF examinations to assess treatment response.
Patients who have neurosyphilis or syphilitic eye disease (e.g., uveitis,
neuroretinitis, or optic neuritis) and who are not allergic to penicillin
should be treated with the following regimen:
Recommended Regimens
If compliance with therapy can be ensured, patients may be treated with the
following alternative regimen:
The durations of the recommended and alternative regimens for neurosyphilis
are shorter than that of the regimen used for late syphilis in the absence
of neurosyphilis. Therefore, some experts administer benzathine penicillin,
2.4 million units IM, after completion of these neurosyphilis treatment regimens
to provide a comparable total duration of therapy.
Other Management Considerations
Follow-Up
Special Considerations
Data have not been collected systematically for evaluation of therapeutic
alternatives to penicillin for treatment of neurosyphilis. Patients who report
being allergic to penicillin should either be densensitized to penicillin
or be managed in consultation with an expert. In some situations, skin testing
to confirm penicillin allergy may be useful (see Management of Patients Who
Have a History of Penicillin Allergy).
Pregnancy
HIV Infection
Syphilis in HIV-Infected Persons
When clinical findings suggest that syphilis is present, but serologic tests
are nonreactive or unclear, alternative tests (e.g., biopsy of a lesion,
darkfield examination, or direct fluorescent antibody staining of lesion
material) may be useful.
Neurosyphilis should be considered in the differential diagnosis of neurologic
disease in HIV-infected persons.
Treatment
for HIV-negative patients. Careful follow-up after therapy is essential.
Primary and Secondary Syphilis in HIV-Infected Persons
Other Management Considerations
Follow-Up
HIV-infected patients who meet the criteria for treatment failure should
be managed the same as HIV-negative patients (i.e., a CSF examination and
re-treatment). CSF examination and re-treatment also should be strongly
considered for patients whose nontreponemal test titer does not decrease
fourfold within 6-12 months. Most experts would re-treat patients with 7.2
million units of benzathine penicillin G (administered as three weekly doses
of 2.4 million units each) if CSF examinations are normal.
Special Considerations
Penicillin-allergic patients who have primary or secondary syphilis and HIV
infection should be managed according to the recommendations for
penicillin-allergic HIV-negative patients.
Latent Syphilis in HIV-Infected Persons
HIV-infected patients who have either late latent syphilis or syphilis of
unknown duration should have a CSF examination before treatment.
Treatment
Follow-Up
Special Considerations
Penicillin regimens should be used to treat all stages of syphilis in
HIV-infected patients. Skin testing to confirm penicillin allergy may be
used (see Management of Patients Who Have a History of Penicillin Allergy).
Patients may be desensitized, then treated with penicillin.
Syphilis During Pregnancy
Diagnostic Considerations
Treatment
Recommended Regimens
Women treated for syphilis during the second half of pregnancy are at risk
for premature labor and/or fetal distress if the treatment precipitates the
Jarisch-Herxheimer reaction. These women should be advised to seek obstetric
attention after treatment if they notice any contractions or decrease in
fetal movements. Stillbirth is a rare complication of treatment, but concern
for this complication should not delay necessary treatment. All patients
who have syphilis should be offered testing for HIV infection.
Follow-Up
Management of Sex Partners
Special Considerations
There are no proven alternatives to penicillin for treatment of syphilis
during pregnancy. Pregnant women who have a history of penicillin allergy
should be desensitized and treated with penicillin. Skin testing may be helpful
(see Management of Patients Who Have a History of Penicillin Allergy).
Tetracycline and doxycycline usually are not used during pregnancy. Erythromycin
should not be used, because it does not reliably cure an infected fetus.
Data are insufficient to recommend azithromycin or ceftriaxone.
HIV Infection
|